ArticleJournal of pharmacy & bioallied sciences2026
Evaluation of Liver Fibrosis and Metabolic Risk in Non-Alcoholic Fatty Liver Disease.
Article in Journal of pharmacy & bioallied sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) has become one of the most common chronic liver disorders worldwide. In India, its burden is rising fast due to increasing metabolic problems like diabetes, obesity, and dyslipidemia. The disease varies from simple fat accumulation to steatohepatitis and cirrhosis. This study aimed to assess the clinical, biochemical and imaging profile of NAFLD patients in a tertiary hospital at Dehradun, Uttarakhand. Methods: A hospital-based cross-sectional study was done for 12 months in the Department of General Medicine, Himalayan Institute of Medical Sciences. Ninety-one adults (≥18 years) diagnosed with NAFLD on ultrasonography were included. Patients with alcohol intake, viral hepatitis, or hepatotoxic drug use were excluded. Demographic data, laboratory values, and imaging findings were recorded. Fibrosis was assessed using liver elastography and NAFLD Fibrosis Score (NFS). Results: Out of 91 patients, 56 (61.5%) were males, mean age 53.1 ± 11.6 years. All had type 2 diabetes and 73 (80.3%) were diabetic for ≥6 years. Dyslipidemia seen in 57.1% and albuminuria in 60.4%. On ultrasonography, 69 patients (75.8%) had Grade II/III steatosis. Elastography showed significant fibrosis (≥F3) in 31 (34.1%) and NFS showed advanced fibrosis in 16 (17.6%). Mean HbA1c was 9.2% showing poor glycemic control. Conclusion: NAFLD patients in north India had high metabolic burden with poor diabetes control, dyslipidemia, and early kidney changes. About one-third already showed significant fibrosis. Early screening and integrated management focusing on metabolic control are essential to prevent disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.